The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Its flagship products - experimental drugs AEGR-733 and AEGR-427 - are MTP (microsomal triglyceride transfer protein) inhibitors, drugs which block a protein that incites cholesterol production in the liver and intestine. Cutting LDL levels may add years to patients' lives but must be weighed against potential side effects such as fat accumulation in the liver, which can lead to inflammation, scarring, and cirrhosis.

CSL Limited is a biopharmaceutical company engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates in three segments: CSL Behring, which is engaged in manufacturing, marketing and developing plasma products; Intellectual Property Licensing, which is engaged in licensing to unrelated third parties of intellectual property generated by the Company, and Other Human Health, which comprises CSL Bioplasma and CSL Biotherapies. These businesses manufacture and distribute biotherapeutic products. It operates in Australia, United States, Switzerland and Germany.

ZymoGenetics, Inc. company was founded in 1981 and is headquartered in Seattle, Washington. ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its products include RECOTHROM, a recombinant thrombin, which is a topical hemostatic agent used for the control of moderate bleeding during surgical procedures. The company's product candidates in clinical development stages include PEG-IFN-l, a pegylated version of the IFN-l1 protein, which is in Phase Ib clinical trials for the treatment of viral infections and autoimmune diseases; IL-21 for the treatment of metastatic melanoma and metastatic renal cell carcinoma; IL-21 monoclonal antibody (mAb) to treat inflammatory diseases; and IL-31 mAb for the treatment of atopic dermatitis and inflammatory diseases. Its out-licensed product candidates include atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; Augment Bone Graft for orthopedic fracture and other bone defects; rFactor XIII for congenital factor XIII deficiency, cardiac surgery, and cancer related bleeding; Fibroblast growth factor-18 for osteoarthritis; IL-17 receptor C for inflammatory diseases; and IL-20 and IL-22 receptor subunit alpha for psoriasis. The company also offers out-licensed commercial products comprising Novolin and insulin analogs for diabetes; NovoSeven for the treatment of hemophilia; Regranex for wound healing; GEM 21S for periodontal defects; GlucaGen for hypoglycemia and gastrointestinal motility inhibition; and Cleactor for treatment of myocardial infarction. ZymoGenetics has collaboration agreements with Bayer Schering Pharma AG; Bristol-Myers Squibb Company; and Merck Serono S.A.

CytRx Corporation company was founded in 1985 and is headquartered in Los Angeles, California. CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology.

Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Pharmacyclics's products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer.

Nuvo Research Inc. primarily focuses on the research and development of drug products that are delivered to and through the skin in Canada. It develops drugs based on two technology platforms, transdermal drug delivery and immune system regulation. The company’s lead products include Pennsaid, a topical non-steroidal anti-inflammatory drug, which is used to treat the pain and symptoms of osteoarthritis of the knee; and Pennsaid Plus, a pre clinical stage product used for applications in various therapeutic areas. Nuvo Research Inc. markets its Pennsaid products in Canada and the Caribbean, as well as in European countries, such as Greece, Italy, and the United Kingdom. Its products also comprise Oxoferin, a topical wound healing agent; and WF10, a chlorite-based, immunomodulating drug, which is in the Phase II clinical trial used for the treatment of inoperable pancreatic cancer. It markets its Oxoferin drug in Europe, Asia, and South America under the Oxoferin and Oxovasin trade names.

Diosynth Biotechnology is all about the cGMP and protein. The company is a leading provider of cGMP (Current Good Manufacturing Practices) production for recombinant therapeutic proteins and peptides. Diosynth's line of proteins include monoclonal antibodies, cancer vaccines, fusion proteins, hormones, cancer vaccines, and anti-coagulants. The company also offers contract manufacturing, process development, and validation services. Diosynth has manufacturing facilities in the US, serving a wide range of customers. The company (which originally began operating in 1923) was a subsidiary of Akzo Nobel until Schering-Plough bought that company's pharmaceutical operations in 2007.

Bio-Engineered Supplements & Nutrition, Inc. ompany makes bodybuilding supplements and sports nutrition products that are distributed in 70 countries. Its line of about 12 supplements come in capsules, liquids, and powders, and they're sold online or at retailers such as GNC. BSN uses professional bodybuilders who act as spokesmodels to sell the products. It recently teamed up with the Ultimate Fighting Championship for a cross-promotional marketing campaign. The company also sells men's and women's clothing and accessories under the TLF Apparel brand (for Train Like A Freak). BSN was founded in 2001 by President and CEO Chris Ferguson.

Stellar Pharmaceuticals Inc. company was founded in 1978 and is based in London, Canada. Stellar Pharmaceuticals Inc. engages in the development and marketing of polysaccharide-based therapeutic products used in the treatment of osteoarthritis and cystitis. It offers NeoVisc, a three injection sodium hyaluronate therapy for the treatment of osteoarthritis; and Uracyst for the treatment of interstitial cystitis, a painful bladder syndrome an inflammatory disease of the urinary bladder wall. The company also has in-licensing agreement for the distribution and sale of BladderChek, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. Stellar markets its products to medical physicians, pharmacies, hospitals, and patient support groups in Canada through its sales force, as well as out-licenses its products to companies in the United States, Europe, Romania, the Russian Federation, China, Israel, the Middle East, Latin America, the Caribbean, Malaysia, Singapore, and Brunei.

Epigenomics AG is a Germany-based company engaged in the molecular diagnostics sector. It divides its products into two areas: solutions for early diagnosis of cancer and products for special diagnosis of cancer. Epigenomics AG produces and develops tests that help in the diagnosis of the colorectal, prostate and lung cancer. The Company also offers services in the field of identification and development of methylated deoxyribonucleic acid (DNA) biomarkers. Industry partners and the medical and life science communities can access the Company’s portfolio of filed patent families covering DNA methylation technologies and biomarkers, as well as its DNA methylation expertise through research products, biomarker services, in vitro diagnostics (IVD) development collaborations and licensing. It develops its solutions together with its commercial partners, Abbott Molecular Inc and Quest Diagnostics Inc. The Company has a subsidiary in the United States, Epigenomics, Inc.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.